SOMATROGON-GHLA: 1,057 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,057
Total FAERS Reports
2 (0.2%)
Deaths Reported
36
Hospitalizations
1,057
As Primary/Secondary Suspect
5
Life-Threatening
4
Disabilities
Prescription
Status
FDA Application: 761184 ·
First Report: 20220101 · Latest Report: 20250925
What Are the Most Common SOMATROGON-GHLA Side Effects?
#1 Most Reported
Injection site pain
738 reports (69.8%)
#2 Most Reported
Wrong technique in device usage process
43 reports (4.1%)
#3 Most Reported
Injection site erythema
42 reports (4.0%)
All SOMATROGON-GHLA Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Injection site pain | 738 | 69.8% | 0 | 2 |
| Wrong technique in device usage process | 43 | 4.1% | 0 | 0 |
| Injection site erythema | 42 | 4.0% | 0 | 0 |
| Incorrect dose administered by device | 41 | 3.9% | 0 | 0 |
| Injection site swelling | 38 | 3.6% | 0 | 0 |
| Off label use | 29 | 2.7% | 0 | 3 |
| Patient-device incompatibility | 29 | 2.7% | 0 | 0 |
| Headache | 27 | 2.6% | 0 | 3 |
| Needle issue | 27 | 2.6% | 0 | 0 |
| Device mechanical issue | 24 | 2.3% | 0 | 0 |
| Device delivery system issue | 23 | 2.2% | 0 | 0 |
| Incorrect dose administered | 22 | 2.1% | 0 | 0 |
| Drug dose omission by device | 21 | 2.0% | 0 | 0 |
| Injection site mass | 21 | 2.0% | 0 | 0 |
| Device leakage | 19 | 1.8% | 0 | 0 |
| Crying | 18 | 1.7% | 0 | 0 |
| Product communication issue | 18 | 1.7% | 0 | 0 |
| Device issue | 17 | 1.6% | 0 | 0 |
| Injection site bruising | 17 | 1.6% | 0 | 1 |
| Injection site pruritus | 17 | 1.6% | 0 | 0 |
Who Reports SOMATROGON-GHLA Side Effects? Age & Gender Data
Gender: 36.4% female, 63.6% male. Average age: 10.3 years. Most reports from: JP. View detailed demographics →
Is SOMATROGON-GHLA Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2022 | 9 | 0 | 0 |
| 2023 | 206 | 0 | 8 |
| 2024 | 161 | 1 | 12 |
| 2025 | 73 | 0 | 5 |
What Is SOMATROGON-GHLA Used For?
| Indication | Reports |
|---|---|
| Growth hormone deficiency | 373 |
| Dwarfism | 110 |
| Hypopituitarism | 38 |
| Short stature | 31 |
| Blood growth hormone | 5 |
| Blood growth hormone decreased | 5 |
SOMATROGON-GHLA vs Alternatives: Which Is Safer?
SOMATROGON-GHLA vs SOMATROPIN
SOMATROGON-GHLA vs SPIRAMYCIN
SOMATROGON-GHLA vs SUFENTANIL
SOMATROGON-GHLA vs SULBACTAM
SOMATROGON-GHLA vs SULFAMETHOXAZOLE\TRIMETHOPRIM
SOMATROGON-GHLA vs SYNTHROID
SOMATROGON-GHLA vs TAZOBACTAM
SOMATROGON-GHLA vs TEDIZOLID
SOMATROGON-GHLA vs TEDUGLUTIDE
SOMATROGON-GHLA vs TEICOPLANIN
Official FDA Label for SOMATROGON-GHLA
Official prescribing information from the FDA-approved drug label.